Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2019-08-13 Interim / Quarterly Rep…
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q1 2019
2019-08-13 English
NOTICE AND PROXY STATEMENT
Proxy Solicitation & Information Statement
2019-07-29 English
FORM 10-K
Annual Report FY 2019
2019-07-01 English
FORM 8-K
Share Issue/Capital Change Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 19, 2019, by Sonoma Pharmaceuticals, Inc. The key content is the announcement of a 1-for-9 reverse stock split of the company's common stock, effective June 19, 2019. It includes details about the stock split approval by stockholders and the Board of Directors' authorization. The document also references the filing of a certificate of amendment with the Secretary of State of Delaware. There are no financial statements or detailed financial data presented, only a corporate action related to capital structure. This fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other categories. The document length is 3719 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is SHA (Share Issue/Capital Change).
2019-06-19 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 11, 2019, reporting the submission of matters to a vote of security holders at a special meeting. It details the voting results on a reverse stock split proposal. The content focuses on the voting results and shareholder meeting outcomes rather than the meeting materials or the full annual report. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4511 characters, which is sufficient to contain substantive voting results rather than just an announcement of a report. Therefore, the correct classification is DVA.
2019-06-12 English
DEFINITIVE ADDITIONAL PROXY MATERIALS
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Definitive Additional Proxy Materials filing (DEFA14A) related to a Special Meeting of Stockholders. It includes a notice of adjournment of the special meeting and instructions for voting on a proposal regarding a reverse stock split. The content is focused on proxy solicitation and voting information rather than the actual proxy statement or meeting materials themselves. The document length is 4154 characters, which is relatively short and consistent with a proxy solicitation or additional proxy materials rather than a full report. Therefore, the document fits best under Proxy Solicitation & Information Statement (PSI).
2019-05-31 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.